Discovery of the first potent proteolysis targeting chimera (PROTAC) degrader of indoleamine 2,3-dioxygenase 1

Cancer immunotherapy is revolutionizing oncology and has emerged as a promising strategy for the treatment of multiple cancers. Indoleamine 2,3-dioxygenase 1 (IDO1), an immune checkpoint, plays an important role in tumor immune escape through the regulation of multiple immune cells and has been rega...

Täydet tiedot

Tallennettuna:
Bibliografiset tiedot
Julkaisussa:Acta Pharm Sin B
Päätekijät: Hu, Mingxing, Zhou, Weilin, Wang, Yijie, Yao, Dongping, Ye, Tinghong, Yao, Yuqin, Chen, Bin, Liu, Gongping, Yang, Xifei, Wang, Wei, Xie, Yongmei
Aineistotyyppi: Artigo
Kieli:Inglês
Julkaistu: Elsevier 2020
Aiheet:
Original Article
Linkit:https://ncbi.nlm.nih.gov/pmc/articles/PMC7606109/
https://ncbi.nlm.nih.gov/pubmed/33163345
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.apsb.2020.02.010
Tagit: Lisää tagi
Ei tageja, Lisää ensimmäinen tagi!

Samankaltaisia teoksia